Araştırmacı İlaç Firmaları Derneği

Name

Araştırmacı İlaç Firmaları Derneği

Legal name

Araştırmacı İlaç Firmaları Derneği

Website

https://aifd.org.tr

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Sisli

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels6 records

Core offering

AIFD is a non-profit industry association that represents 38 multinational research-based pharmaceutical companies operating in Turkey. Its core offerings are policy advocacy, industry intelligence (annual Türkiye İlaç Sektörü Raporu prepared with IQVIA, Türkiye'de Nadir Hastalıklar report), ethical-promotion governance (AIFD Code of Promotion), professional education programs (İyi Klinik Uygulamaları training, BIO Startup Program, Patient Associations Development Academy), and awareness campaigns (hepimizicinumut.com) — delivered to member companies, regulators, healthcare professionals, patient associations, and academia.

Product overview

Araştırmacı İlaç Firmaları Derneği (AIFD) is an industry association representing 38 multinational research-based pharmaceutical companies operating in Turkey. Rather than selling commercial products, AIFD provides advocacy services, publishes industry reports, runs educational programs, and facilitates healthcare innovation initiatives. Key offerings include the Turkey Pharmaceutical Sector Report (prepared with IQVIA and EFPIA), the Rare Diseases Report, the BIO Startup Program for healthcare entrepreneurs, the Patient Associations Development Academy, the AIFD Innovative Medicines Symposium, the #CareBulanaDek campaign website (hepimizicinumut.com), and various guidelines on ethical pharmaceutical promotion and clinical research. The association also provides Good Clinical Practice training programs and maintains a public announcements and legislation repository for pharmaceutical regulations.

Differentiator

Problem solved

Functional benefit

Brands

• hepimizicinumut.com: Innovative Drugs Awareness Campaign website created to spread awareness on how innovative drugs add value to human life
• BIO Startup Program
• AIFD Patient Associations Development Academy

Products and services

• Türkiye İlaç Sektörü Raporu (Turkey Pharmaceutical Sector Report) Annual industry intelligence report analyzing Turkey's pharmaceutical market, prepared with IQVIA and published by AIFD for member companies, regulators, healthcare professionals, and the broader industry audience.
• Sürdürülebilir Değer Bazlı İlaç Fiyatlandırma ve Geri Ödeme Raporu (Sustainable Value-Based Pharmaceutical Pricing and Reimbursement Report) Policy analysis report on sustainable value-based pricing and reimbursement systems for pharmaceuticals, designed for Turkish healthcare decision-makers and member companies.
• Türkiye'de Nadir Hastalıklar Raporu (Rare Diseases in Turkey Report) Industry-initiated report on rare diseases in Turkey, prepared to raise awareness of access and treatment challenges affecting roughly 5 million people with rare conditions.
• BIO Startup Program Bio-entrepreneurship program supporting startups in the healthcare and biotechnology sectors, run by AIFD to foster innovation in Turkey's life sciences ecosystem.
• AIFD Hasta Dernekleri Gelişim Akademisi (Patient Associations Development Academy) Capacity-building program for Turkish patient associations delivering training (e.g. campaign management, digital communications tools) and project support to strengthen patient advocacy organizations.
• İyi Klinik Uygulamaları Eğitimi (Good Clinical Practice Training Program) Good Clinical Practice training program for clinical research professionals, delivered by AIFD under the new Turkish GCP regulation framework across multiple cities in Turkey.
• AIFD Yenilikçi İlaçlar Sempozyumu (Innovative Medicines Symposium) Annual symposium organized by AIFD bringing together industry, government, academia, and healthcare professionals to discuss innovative medicines and value-based pricing and reimbursement in Turkey.
• hepimizicinumut.com Innovative Drugs Awareness Campaign Public awareness campaign website dedicated to communicating the value of innovative medicines to patients and the general public in Turkey.
• AIFD Kamu Duyuruları ve Mevzuat Portalı (Public Announcements and Legislation Portal) Online portal providing access to pharmaceutical-sector regulations and TITCK public announcements, used by member companies and healthcare stakeholders for regulatory reference.

Quantifiable outcome

• 69% increase in clinical research investment to over 17 billion TL in 2024
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered major, strategic and core.

• Istanbul University-CerrahpaşamajorStrategic or Co-development Partner · 1 January 2026AIFD and Istanbul University-Cerrahpaşa collaborate for a more inclusive healthcare system, focusing on academic-industry cooperation in healthcare innovation.
• Golden Pulse Health SummitstrategicGTM or Marketing Partner · 1 January 2026AIFD is a strategic partner of the Golden Pulse Health Summit, participating in discussions on healthcare innovation and showcasing its vision for innovation in healthcare.
• IQVIAmajorStrategic or Co-development Partner · 1 January 2024IQVIA collaborates with AIFD to prepare the annual Turkish Pharma Sector Report, providing comprehensive analysis of the pharmaceutical industry in Turkey.
• TEPAV (Türkiye Ekonomi Politikaları Araştırma Vakfı)majorStrategic or Co-development Partner · 1 January 2016AIFD collaborated with TEPAV to prepare the Pharmaceutical Manufacturing and Export Ecosystem Report, which analyzes Turkey's pharmaceutical industry competitiveness and provides policy recommendations.
• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations)coreStrategic or Co-development Partner · 1 January 2003AIFD is a member of IFPMA, the global organization representing research-based pharmaceutical companies. This membership provides access to international best practices, policy guidance, and global industry collaboration.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreStrategic or Co-development Partner · 1 January 2003AIFD is a member of EFPIA, representing the European pharmaceutical industry. This membership facilitates collaboration with European industry stakeholders, access to regulatory frameworks, and participation in European healthcare initiatives.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations): Global pharmaceutical industry association of which AIFD is a member. IFPMA operates the same advocacy and ethics function as AIFD at worldwide scope, providing AIFD with policy frameworks, international benchmarks, and a global voice that AIFD transmits into Turkish regulatory debates.
• PhRMA (Pharmaceutical Research and Manufacturers of America): U.S. research-based pharma trade association. PhRMA plays an identical role to AIFD in representing multinational research-based pharma in U.S. policy debates (FDA, IRA drug pricing, IP), serving as the benchmark operating model for AIFD's member-services and policy advocacy in Turkey.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): European-level trade association of which AIFD is a member. EFPIA directly serves the same role as AIFD but at pan-European scale, running parallel W.A.I.T. Indicator surveys, value-based pricing advocacy, and ethical promotion codes that AIFD implements locally in Turkey.

Regional players

• JPMA (Japan Pharmaceutical Manufacturers Association): Japan's research-based pharmaceutical trade association. JPMA performs the identical industry-association role as AIFD in a different geography, with comparable focus on innovative drug access, R&D data publication, and government policy advocacy.
• Medicines for Europe: European trade association representing generic and biosimilar medicines manufacturers. While AIFD represents the innovative-medicines side of the industry, Medicines for Europe shapes adjacent policy debates (off-patent competition, biosimilars) that directly affect AIFD members' IP and data-exclusivity positions in Turkey.
• Medicines Australia: Australia's research-based pharma industry association. Medicines Australia performs the same member-advocacy, code-of-conduct, and reimbursement-policy role as AIFD, making it a useful operational and policy comparator from another single-payer-adjacent market.
• ABPI (Association of the British Pharmaceutical Industry): UK research-based pharma trade association. ABPI executes the same mandate as AIFD — code of practice, policy advocacy, member R&D data publication — but in the UK NHS/MHRA context, providing a comparable operational template for member services and government engagement.

Emerging players

• BIO (Biotechnology Innovation Organization): U.S.-based biotech trade association. AIFD's BIO Startup Program mirrors BIO's biotechnology-ecosystem-building mission and annual convention, making BIO a comparable peer on the innovation/startup-convening dimension of AIFD's work.

Direct peers

• İlaç Endüstrisi İşverenler Sendikası (İEİS): Turkish pharmaceutical industry employers' association, the closest domestic peer to AIFD. İEİS represents a broader swath of Turkish pharma manufacturers including local generic producers, making it a direct competitor for policy influence on Turkish pricing, reimbursement, and industrial policy.
• TİSD (Türkiye İlaç ve Serum Sanayicileri Derneği): Turkish association of pharmaceutical and serum manufacturers. TİSD represents the local/domestic pharma manufacturing side of the Turkish market and competes with AIFD for influence over Turkish industrial, manufacturing, and reimbursement policy, particularly on localization and IP issues.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/aifd_iletisim
• Facebookfacebook.com/aifd.iletisim
• LinkedInlinkedin.com/company/aifd-iletisim

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Araştırmacı İlaç Firmaları Derneği